Association between apnea-hypopnea index and coronary artery calcification: a systematic review and meta-analysis

Wen Hao,a,b, Xiao Wang,a,b, Jingyao Fan,a,b, Yaping Zeng,a,b, Hui Ai,a,b, Shaoping Nie,a,b and Yongxiang Wei,b,c

aEmergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; bBeijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China; cDepartment of Otolaryngology Head and Neck Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

ABSTRACT
Background: The present study aimed to evaluate the association between presence and severity of obstructive sleep apnoea (OSA) and the presence of subclinical coronary artery disease (CAD) as assessed by coronary calcium score.

Methods: Medline, Cochrane, and Google Scholar databases were searched. The presence of coronary artery calcification (CAC) and CAC score were assessed.

Results: Irrespective of the cut-off value of apnoea-hypopnea index (AHI) (5 or 15 events/h), patients in the OSA group had higher rate of CAC presence and mean CAC score than those in the control group. Subgroup analyses of patients monitored with home sleep apnoea testing (HSAT) or in-hospital/laboratory polysomnography showed that the OSA group had higher rate of CAC presence and mean CAC score than the control group, except in the comparison of mean CAC score between AHI ≥5 vs. <5 events/h for patients using HSAT, which was not significant. Pair-wise comparison showed that CAC score may increase with increased OSA severity.

Conclusions: In participants without symptomatic coronary disease, the presence of OSA was associated with the presence and extent of CAC. However, potential confounders such as age, gender, and BMI and the diversity of CAC scores may affect the association.

ARTICLE HISTORY
Received 6 September 2020
Revised 21 December 2020
Accepted 6 January 2021

KEYWORDS
Obstructive sleep apnoea; apnoea-hypopnea index; coronary artery calcification; coronary calcium score; subclinical coronary artery disease

Introduction
Obstructive sleep apnoea (OSA) is the most common type of sleep disordered breathing and is characterised by repeated episodes of complete or partial obstruction of the upper airway during sleep [1]. Approximately 1 billion adults aged between 30 and 69 years worldwide are estimated to exhibit OSA. According to the American Academy of Sleep Medicine, OSA syndrome is defined as an apnea-hypopnea index (AHI) ≥5 events/h associated with symptoms (e.g. excessive daytime sleepiness, impaired cognition, mood disorders, or insomnia, or documented hypertension, ischaemic heart disease, or history of stroke) or an AHI ≥15 events/h, regardless of associated symptoms [2]. The reported prevalence of OSA varied from 7.8% (Hong Kong) to 77.2% (Malaysia) with an AHI ≥5 events/h and from 4.8% (Ireland and Israel) to 36.6% (Switzerland) with an AHI ≥15 events/h [3]. The prevalence of OSA is disproportionately high in patients with cardiovascular disorders relative to the general population: hypertension (30–83%), ischaemic heart disease (30–58%), stroke (43–91%), heart failure (12–53%), and peripheral arterial disease (78–85%) [4–7]. Untreated OSA was associated with increased risk for cardiovascular morbidities, including stroke, hypertension, heart failure, and coronary artery disease (CAD), and increased risk of cardiovascular mortality [8]. Moreover, according to our previous research, OSA was associated with worse cardiovascular outcomes in patients with acute coronary syndrome in a cohort study as well as in patients who underwent percutaneous coronary intervention as revealed in a systematic review and meta-analysis [9,10]. According to findings of a systematic review and meta-analysis, the use of continuous positive airway pressure in patients with CAD and OSA may help prevent subsequent cardiovascular events [11].
Scoring coronary artery calcification (CAC) using computed tomography is a non-invasive assessment for individuals at risk for coronary atherosclerosis, and its use is becoming increasingly widespread [12]. CAC score was reported to be a strong predictor of CAD, and the risk of coronary events was increased with an increase in stratum of CAC score with the largest increase in risk associated with CAC scores >100 [13,14]. Although no randomised clinical trial has yet evaluated the effect of treatment according to CAC score, a considerable number of epidemiological and observational studies have provided convincing data worthy of consideration as guidance in clinical decision-making [12]. Furthermore, the use of CAC score to risk stratify asymptomatic patients has been considered appropriate/recommended by international guidelines; however, for symptomatic patients, the use of CAC score alone is limited [15].

An accumulating number of studies have investigated the link between OSA and subclinical coronary atherosclerosis assessed by CAC; however, the results have not been consistent. Some studies revealed that AHI was independently associated with CAC and that CAC score increased with OSA severity assessed by AHI, whereas other studies showed that the association was no longer significant after adjustment for possible confounders such as age, gender, and CAD risk factors [16–21]. The inconsistencies reflect the complex interactions between OSA, CAC, and traditional cardiovascular risk factors.

The purpose of the current systematic review and meta-analysis was to evaluate whether the presence of CAC and CAC score are associated with the presence of OSA using the AHI cut-off values of 5 and 15 events/h.

Methods

Search strategy

The study was conducted in accordance with the PRISMA guidelines [22]. Medline, Cochrane, and Google Scholar databases were searched up to April 29, 2020. The search terms used were: (obstructive sleep apnoea) OR (sleep characteristics) OR (sleep disturbance) OR (sleep disordered breathing); (coronary artery calcification) OR (coronary calcium) OR (coronary artery calcium); (subclinical coronary atherosclerosis) OR (subclinical coronary artery disease) OR (subclinical cardiovascular disease). The inclusion criteria were 1) clinical studies that included subjects with no known cardiovascular disease; 2) the severity of OSA was assessed by AHI; 3) the rate of CAC presence and/or CAC scores were reported; 4) English-language publications. Review articles, letters, books, commentaries, editorials, case reports, meeting proceedings, and personal communications were excluded. Studies designed for patients with end-stage renal disease or pulmonary fibrosis were also excluded.

A two-step process was used to screen the potential studies: (1) the title and abstract of each study was examined, and studies not meeting the inclusion criteria or meeting the exclusion criteria were discarded; (2) the full text of the remaining studies were examined for fulfilment of all inclusion criteria and none of the exclusion criteria. Two independent reviewers utilised the search strategy to identify eligible studies. A third reviewer was consulted if there was uncertainty regarding eligibility. The reference lists of relevant studies were searched manually to identify additional eligible studies.

Data extraction

The following data were extracted from the included studies: name of the first author; year of publication; study design; number of participants in each group; participants’ age, gender and body mass index (BMI); comorbidities including hypertension, diabetes and dyslipidemia; polysomnographic findings including AHI, oxygen saturation and oxygen desaturation index; and major outcomes of CAC presence rate and CAC score.

Quality assessment

The quality of the included studies was assessed using the 11 items suggested by the U.S. Agency for Healthcare Research and Quality (AHRQ) for assessing the quality of cross-sectional studies [23].

Statistical analysis

The clinical characteristics were summarised as mean±standard deviation (SD) or median (interquartile, IQR) for continuous variables, and n(%) for categorical ones. For the primary outcome, the presence of CAC defined as CAC score >0 was summarised as n(%) according to OSA severity classification. For the secondary outcome, CAC score was summarised as mean±SD, mean (IQR), median (IQR), or median (range) according to OSA severity classification. Classification of OSA severity was defined based on AHI: normal (AHI <5 events/h), mild (AHI ≥5 to <15 events/h), moderate (AHI ≥15 to <30 events/h), or
severe (AHI ≥30 events/h) [2]. For meta-analysis, data were combined for two major comparisons: AHI ≥5 (OSA group) vs. <5 (control group) events/h and ≥15 (OSA group) vs. AHI <15 (control group) events/h. Moreover, the estimated sample mean and SD for CAC score were generated when data were presented with mean (IQR), median (IQR), or median (range) before proceeding with meta-analysis [24]. The measure of effect size for the presence of CAC was defined as odds ratio (OR) with 95% confidence interval (CI) and p value, and a combined effect was calculated thereby among those studies with complete measurements. An OR >1 indicated the rate of CAC presence was higher in the OSA group than in the control group, an OR <1 indicated the rate of CAC presence was lower in the OSA group than in the control group, and an OR of 1 indicated the rate of CAC presence was similar between groups.

The measure of effect size for CAC score was defined as difference in means of CAC score between groups with 95% CI and p value, and a combined effect was calculated thereby among those studies with complete measurements. For effect size, a difference in means >0 indicated the OSA group might have higher mean CAC score than the control group; a difference in means <0 indicated the OSA group might have lower mean CAC score than the control group; and a difference in means of 0 indicated CAC score was similar between groups.

Study heterogeneity was presented using a $\chi^2$-based Cochran’s Q statistic and $I^2$ statistic [25]. For the $Q$ statistic, a corresponding p value of <.10 was considered statistically significant for heterogeneity. For the $I^2$ statistic, heterogeneity was assessed as follows: no heterogeneity ($I^2 = 0 – 25\%$), moderate heterogeneity ($I^2 = 25 – 50\%$), large heterogeneity ($I^2 = 50 – 75\%$), and extreme heterogeneity ($I^2 = 75 – 100\%$). If p value was <.10 for $\chi^2$-based Cochran’s Q statistic or if $I^2 > 50\%$, a random-effect model was considered to estimate the pooled effect; otherwise, a fixed-effect model was performed [26]. A two-sided p value of <.05 was considered significant. A sensitivity analysis was conducted using a leave-one-out approach. Publication bias was not assessed due to the small number of included studies [27]. A subgroup analysis was performed to calculate the pooled effect in patients monitored with home sleep apnoea testing (HSAT) or in-hospital/laboratory polysomnography (PSG). Moreover, pairwise comparisons among OSA severity groups were performed to evaluate the association of the presence of CAC and CAC score with OSA severity. All statistical analyses were performed using the statistical software Comprehensive Meta-Analysis, version 2.0 (Biostat, Englewood, NJ).

Results

Search results

The flow diagram of study selection is shown in Figure 1. A total of 3325 articles were initially screened using titles and abstracts, of which 3259 were excluded. After full-text review of the remaining of 66 articles, 53 studies were excluded, and the reasons for exclusion are shown in Figure 1. Therefore, 13 articles were included in the systematic review [16–20,28–35]. Subjects in Matthews et al. [35], Luyster et al. [34], and Shipilsky et al. [30] were recruited from the Heart Strategies Concentrating on Risk Evaluation (HeartSCORE) study; among these, Shipilsky et al. [30] was the only study not included in the meta-analysis. Seo et al. [19] and Hamaoka et al. [31] reported data in a form that could not be pooled with data from the other studies. Ultimately, 10 studies were included in the meta-analysis.

Characteristics of included studies

The characteristics of the included studies are summarised in Table 1. 12 studies were cross-sectional in design. Overall, 6620 subjects were included, with mean age ranging from 46 to 69.1 years and proportion of males ranging from 0 to 92.8%. Mean BMI ranged from 23.8 to 35 kg/m². Reported comorbidities and polysomnographic recordings are also summarized in Table 1. Overall, the percentage of patients with hypertension ranged from 21 to 95%. The percentage of patients with diabetes ranged from 4 to 43.2%. Included in the 10 studies comprising the meta-analysis were 2,450 patients without OSA (AHI < 5) and 3,677 patients with mild to severe OSA (AHI ≥ 5). In terms of OSA severity, 4,406 patients had no to mild OSA (AHI < 15) and 1,456 patients had moderate to severe OSA (AHI ≥ 15). Table 2 summarizes the rate of CAC presence and CAC score in each OSA severity group.

Meta-analysis

Association of OSA severity and presence of CAC

Six studies with complete data on CAC presence for the comparison between AHI ≥5 (OSA group) and AHI <5 (control group) events/h were included for meta-analysis [16,18,28,29,33,34]. The rate of CAC presence ranged from 21 to 67.2% in the control group and
from 29.4 to 78% in the OSA group. A random-effect model was applied according to the results of heterogeneity tests (Q-value = 11.50, df = 5, p value = .042, \( I^2 = 56.51\% \)). The combined effect revealed that patients in the OSA group might have a higher rate of CAC presence compared with those in the control group (pooled OR = 1.896, 95%CI = 1.423–2.526, \( p \) value < .001) (Figure 2(A)).

Four studies with complete data on the presence of CAC for the comparison of AHI ≥15 (OSA group) and AHI <15 (control group) events/h were included for meta-analysis [16,28,33,34]. The rate of CAC presence ranged from 20 to 70.2% in the control group and from 36.3 to 84.0% in the OSA group. A fixed-effect model was applied according to results of heterogeneity tests (Q-value = 3.17, df = 3, \( p \) value = .365, \( I^2 \) = 5.54%). The combined effect revealed that patients in the OSA group might have a higher rate of CAC presence compared with those in the control group (pooled OR = 1.763, 95%CI = 1.501 to 2.071, \( p \) value < .001) (Figure 2(B)).

Results of the subgroup analyses showed that regardless of the cut-off value of AHI (5 or 15 events/h) used, the OSA group might have a higher rate of
| First author (published year) | Study design | Trial name | Country | Ethnicity | OSA severity | Assessment of OSA | Number of patients | Age (Mean ± SD years) | Sex, Males (%) | BMI (Mean ± SD kg/m²) |
|------------------------------|--------------|------------|---------|-----------|--------------|-------------------|--------------------|---------------------|-----------------|---------------------|
| Kim (2020) CS KoGES Korea | –            | Normal     | HSAT    | 1096      | 58.8 ± 6.0  | 456 (42)          | 23.8 ± 2.6         |
| Bikov (2019) CS Hungary | –            | Normal     | HSAT    | 361       | 62.1 ± 7.6  | 246 (68)          | 26.1 ± 3.3         |
| Shipilsky (2018) CS USA | –            | Normal/Mild| HSAT (ApneaLink) | 561 | 58.7 ± 7.7  | 159 (28)          | 30.6 ± 5.6         |
| Hamaoka (2018) CS Japan | –            | Normal     | HSAT    | 15        | 61.3 ± 12.4 | 11 (73.3)         | 26.3 ± 5.0         |
| Seo (2017) CS Korea | –            | Normal     | HSAT    | 64        | 55.08 ± 7.6 | 428 (92.8)        | 25.57 ± 3.01       |
| Medeiros (2017) CS Brazil | –            | Normal     | HSAT    | 132       | 55 (51–59)  | 0 (0)             | 27(24–29)          |
| Lutsey (2015) CS MESA USA | –            | Normal     | HSAT    | 214       | 58 (53–63)  | 0 (0)             | 32 (29–35)         |
| Luyster (2014) CS Heart SCORE USA | –            | Normal     | HSAT (ApneaLink) | 61 | 59.1 ± 7.8  | 29 (48)           | 29.0 ± 5.8         |
| Arik (2013) Pro Turkey | –            | Normal     | HSAT    | 16        | 50 ± 10     | 9 (56)            | 28.2 ± 4.8         |
| Weinreich (2013) CS Nixdorf Recall German | –            | Normal (M) | HSAT (ApneaLink) | 209 | 61.9 ± 6.9  | 209 (100)         | 27.6 ± 3.6         |
| Matthews (2011) CS HeartSCORE ≥ SleepSCORE USA | –            | Normal     | HSAT    | 63        | 68.5 ± 5.7  | 0 (0)             | 30.9 ± 4.1         |
| Kepez (2011) CS Turkey | –            | Normal     | HSAT    | 17        | 46.60 ± 4.39 | 10 (58.8)          | 28.25 ± 4.04       |
| Sorajja (2008) CS USA | –            | Normal     | HSAT    | 48        | mean = 46   | 30 (63)           | mean = 31          |

OSA severity group was defined according to apnoea-hypopnea index (AHI): normal (AHI <5 events/h), mild (AHI ≥ 5 to < 15 events/h), moderate (AHI ≥15 to <30 events/h), or severe (AHI ≥30 events/h).

*median (IQR).

CS: cross-sectional; F: female; HSAT: home sleep apnoea testing; M: male; OSA: obstructive sleep apnoea; Pro: prospective study; PSG: polysomnography.
| First author (published year) | OSA severity group | Hypertension, n (%) | Diabetes, n (%) | Dyslipidemia, n (%) | AHI, Mean ± SD event/h | Mean SaO₂, Mean ± SD % | Lowest SaO₂, Mean ± SD % | Oxygen desaturation index, Mean ± SD event/h |
|-------------------------------|--------------------|---------------------|----------------|---------------------|------------------------|------------------------|--------------------------|-----------------------------------|
| **Kim (2020)**                | Normal             | 374 (94.1)          | 281 (75.6)     | N/A                 | 2.1 ± 1.4              | 95.9 ± 1.1             | 89.6 ± 5.3                | 1.9 ± 0.3                         |
|                              | Mild               | 353 (90.4)          | 227 (62.4)     | N/A                 | 8.7 ± 2.7              | 95.2 ± 1.2             | 85.1 ± 4.7                | 7.9 ± 2.9                        |
|                              | Moderate to Severe | 226 (62.6)          | 156 (43.2)     | N/A                 | 26.1 ± 12.1            | 94.4 ± 1.5             | 80.4 ± 6.7                | 24.0 ± 11.6                      |
| **Bikov (2019)**              | Normal             | 12 (63)             | 3 (16)         | 10 (53)             | 1.8 ± 1.1              | N/A                    | N/A                       | 89.8 ± 3.1                       |
|                              | Mild, Moderate to Severe | 34 (77)           | 8 (18)         | 22 (50)             | 18.8 ± 16.3            | N/A                    | N/A                       | 83.9 ± 3.9                       |
| **Shipilsky (2018)**          | Normal/Mild        | 199 (36)            | 43 (8)         | N/A                 | 5.9 ± 3.8              | N/A                    | N/A                       | N/A                              |
|                              | Moderate to Severe | 104 (51)            | 22 (11)        | N/A                 | 26.1 ± 12.0            | N/A                    | N/A                       | N/A                              |
| **Hamaoka (2018)**            | Mild to Moderate   | 5 (30.0)            | 2 (13.3)       | 3 (20.0)            | 20.7 ± 8.4             | N/A                    | N/A                       | N/A                              |
|                              | Severe             | 9 (52.9)            | 4 (23.5)       | 5 (29.4)            | 45.2 ± 11.9            | N/A                    | N/A                       | N/A                              |
| **Seo (2017)**                | Normal             | 205 (44.5)          | 62 (13.4)      | 268 (58.1)          | 25.46 ± 21.10          | N/A                    | 83.56 ± 7.03              | N/A                              |
|                              | Mild               | 34 (77.2)           | 86 (18.4)      | 23 (51.1)           | 19.8 ± 15.9            | N/A                    | N/A                       | N/A                              |
|                              | Moderate           | 37 (74.5)           | 99 (20.7)      | 51 (10.7)           | 14.9 ± 14.1            | N/A                    | N/A                       | N/A                              |
| **Medeiros (2017)**           | Normal             | 87 (70)             | 32 (24)        | 94 (72)             | 1.9 (0.5–3.3)          | 96 (96–98)             | 91 (89–93)                | N/A                              |
|                              | Mild               | 86 (77)             | 15 (25)        | 45 (75)             | 8.3 (6.0–11.1)         | 96 (95–96)             | 85 (82–88)                | N/A                              |
|                              | Moderate to Severe | 75 (63)             | 19 (39)        | 27 (55)             | 16.9 (15.4–24.5)       | 95 (94–96)             | 80 (75–84)                | N/A                              |
| **Lutsey (2015)**             | Normal             | N/A                 | 90 (19.0)      | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Mild               | N/A                 | 90 (19.0)      | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Moderate           | N/A                 | 90 (19.0)      | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Severe             | N/A                 | 51 (23.8)      | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
| **Luyster (2014)**            | Normal             | 43 (71)             | 10 (16)        | 45 (77)             | 2.7 ± 1.1              | N/A                    | N/A                       | N/A                              |
|                              | Mild               | 65 (67)             | 22 (23)        | 81 (83)             | 9.0 ± 2.7              | N/A                    | N/A                       | N/A                              |
|                              | Moderate to Severe | 71 (75)             | 19 (20)        | 65 (69)             | 26.9 ± 12.3            | N/A                    | N/A                       | N/A                              |
| **Arik (2013)**               | Normal             | 6 (38)              | 4 (25)         | 6 (38)              | 2.4 ± 1.1              | N/A                    | N/A                       | N/A                              |
|                              | Mild               | 5 (36)              | 2 (14)         | 3 (21)              | 8.0 ± 2.0              | N/A                    | 87 ± 10                   | 2.7 ± 3.2                        |
|                              | Moderate           | 4 (21)              | 6 (32)         | 3 (16)              | 22.5 ± 4.3             | N/A                    | 77 ± 12                   | 5.1 ± 3.3                        |
|                              | Severe             | 12 (50)             | 9 (38)         | 9 (38)              | 45.3 ± 16.3            | N/A                    | 71 ± 12                   | 14.6 ± 19.7                      |
| **Weinreich (2013)**          | Normal (M)         | 123 (58.9)          | 27 (12.9)      | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Mild (M)           | 230 (70.3)          | 42 (12.8)      | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Moderate (M)       | 125 (71)            | 26 (14.7)      | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Severe (M)         | 71 (75)             | 19 (20)        | 65 (69)             | 26.9 ± 12.3            | N/A                    | N/A                       | N/A                              |
| **Matthews (2011)**           | Normal (F)         | 149 (43.6)          | 30 (8.8)       | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Mild (F)           | 150 (58.6)          | 30 (9.3)       | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Moderate (F)       | 69 (61.6)           | 13 (11.6)      | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Severe (F)         | 25 (71.4)           | 5 (14.3)       | N/A                 | N/A                    | N/A                    | N/A                       | N/A                              |
| **Kepez (2011)**              | Normal             | 4 (23.5)            | 2 (11.8)       | 2 (12.5)            | N/A                    | 94.30 ± 1.20           | 94.34 ± 1.32              | 0.00 (1.00)                      |
|                              | Mild               | 7 (31.8)            | 2 (9.1)        | 6 (27.3)            | N/A                    | 94.12 ± 1.63           | 94.45 ± 1.53              | 2.00 (2.25)                      |
|                              | Moderate           | 7 (33.3)            | 2 (9.5)        | 5 (23.8)            | N/A                    | 93.04 ± 1.20           | 93.58 ± 1.41              | 4.00 (7.00)                      |
|                              | Severe             | 15 (40.5)           | 7 (18.9)       | 11 (29.7)           | N/A                    | 91.20 ± 1.40           | 92.38 ± 2.48              | 13.00 (24.75)                    |
| **Sorajja (2008)**            | Normal             | 20 (40)             | 2 (4)          | 23 (48)             | N/A                    | N/A                    | N/A                       | N/A                              |
|                              | Mild, Moderate to Severe | 76 (49)           | 14 (9)         | 99 (64)             | N/A                    | N/A                    | N/A                       | N/A                              |

OSA severity group was defined according to apnoea-hypopnea index (AHI): normal (AHI < 5 events/h), mild (AHI ≥ 5 to < 15 events/h), moderate (AHI ≥ 15 to < 30 events/h), or severe (AHI ≥ 30 events/h). AHI: apnoea-hypopnea index; BMI: body mass index; F: female; M: male; SaO₂: oxygen saturation; NA: not available; OSA: obstructive sleep apnoea. #median (IQR).
CAC presence than the control group in patients monitored with either HSAT or in-hospital/laboratory PSG (all ORs >1; p values < .001). The pooled result of in-hospital/laboratory PSG with regard to AHI 15 vs. <15 events/h was not assessed because only one study reported such data. Pair-wise comparison showed that the association between the presence of CAC and OSA severity was significant in patients with mild and moderate OSA compared to patients without OSA (all ORs >1; p values ≤ .001). However, the significance was not observed in patients with moderate-to-severe and severe OSA compared to patients without OSA (Table 3).

**Association of OSA severity and CAC score**

Six studies with complete data on CAC score for the comparison of AHI 5 (OSA group) and AHI <5 (control group) events/h were included for meta-analysis [16,17,20,28,29,34]. Mean CAC scores ranged from 0 to 20.9 in the control group and from 0 to 137.4 in the OSA group. A fixed-effect model was applied according to results of heterogeneity tests (Q-value = 8.681, df = 5, p value=.122, I-square = 42.40%). The combined effect showed that the mean CAC score was higher in OSA group than in control group (difference in means of CAC score = 42.64, 95%CI = 35.34 to 49.94, p value < .001) (Figure 3(A)).

Five studies with complete data on CAC score for the comparison of AHI ≥15 (OSA group) and AHI <15 (control group) events/h were included for meta-analysis [16,17,20,28,34]. Mean CAC scores ranged from 0 to 34.8 in the control group and from 0 to 96.8 in the OSA group. A random-effect model was applied according to results of heterogeneity tests (Q-value = 10.644, df = 4, p value =.031, I-square = 62.42%). The combined effect showed that mean CAC score was

---

**Figure 2.** Forest plot comparing presence of CAC between (A) AHI ≥5 vs. <5 events/h and (B) AHI ≥15 vs. <15 events/h. Abbreviations: 95% CI, 95% confidence interval of odds ratio (lower limit and upper limit).
higher in the OSA group than in the control group (difference in means of CAC score = 40.67, 95%CI = 13.25 to 68.10, p value = .004) (Figure 3(B)).

Results of the subgroup analyses suggest that the OSA group might have higher mean CAC score than the control group in patients monitored with either HSAT or in-hospital/laboratory PSG (all pooled effect, differences in means >0); however, the significance was not observed in the comparison of AHI ≥5 vs. <5 events/h in patients using HSAT. Pair-wise comparison showed that the pooled effect was significantly different for comparisons between moderate, severe, and moderate-to-severe OSA vs. no OSA (differences in means = 46.19, 86.21, and 45.51; p = .003, <.001, and .004, respectively); however, there was no significant difference between mild OSA and no OSA (differences in means = 11.63, p = .241) (Table 3).
The quality of the included studies was evaluated using the ARHQ methodology checklist, and the results are shown in Table 4. All of the included studies reported the source of data, patient inclusion and exclusion criteria, and summarised patient response; however, the completeness of data collection was unclear. Most of the included studies indicated whether participants were consecutive and how confounding was assessed.

**Discussion**

The current systematic review and meta-analysis showed that irrespective of the cut-off value of AHI(5 or 15 events/h), patients in the OSA group had higher rate of CAC presence and mean CAC score than those in the control group. These findings suggest that regardless of the cut-off value of AHI, OSA may be associated with risk of subclinical CAD. However, the pooled results in the current study must be interpreted cautiously due to lack of adjustment for confounding factors. The subgroup analyses showed that the OSA group had higher rates of CAC presence and mean CAC scores than the control group in patients monitored with HSAT or in-hospital/laboratory PSG, with the exception of the comparison of mean CAC scores using AHI cut-off of 5 events/h in patients using HSAT, which was not significant. Pair-wise comparison showed that presence of CAC was associated with mild and moderate OSA but not with severe OSA. Mean CAC scores were significantly higher in patients with moderate and severe OSA than in patients without OSA, suggesting that CAC score increases with OSA severity. Since some analyses included a small number of studies (<3 studies), further studies are needed to confirm the results.

Although the present study showed that presence of OSA was associated with presence and extent of CAC, the current systematic review and meta-analysis showed that irrespective of the cut-off value of AHI(5 or 15 events/h), patients in the OSA group had higher rate of CAC presence and mean CAC score than those in the control group. These findings suggest that regardless of the cut-off value of AHI, OSA may be associated with risk of subclinical CAD. However, the pooled results in the current study must be interpreted cautiously due to lack of adjustment for confounding factors. The subgroup analyses showed that the OSA group had higher rates of CAC presence and mean CAC scores than the control group in patients monitored with HSAT or in-hospital/laboratory PSG, with the exception of the comparison of mean CAC scores using AHI cut-off of 5 events/h in patients using HSAT, which was not significant. Pair-wise comparison showed that presence of CAC was associated with mild and moderate OSA but not with severe OSA. Mean CAC scores were significantly higher in patients with moderate and severe OSA than in patients without OSA, suggesting that CAC score increases with OSA severity. Since some analyses included a small number of studies (<3 studies), further studies are needed to confirm the results.

Although the present study showed that presence of OSA was associated with presence and extent of CAC, the current systematic review and meta-analysis showed that irrespective of the cut-off value of AHI(5 or 15 events/h), patients in the OSA group had higher rate of CAC presence and mean CAC score than those in the control group. These findings suggest that regardless of the cut-off value of AHI, OSA may be associated with risk of subclinical CAD. However, the pooled results in the current study must be interpreted cautiously due to lack of adjustment for confounding factors. The subgroup analyses showed that the OSA group had higher rates of CAC presence and mean CAC scores than the control group in patients monitored with HSAT or in-hospital/laboratory PSG, with the exception of the comparison of mean CAC scores using AHI cut-off of 5 events/h in patients using HSAT, which was not significant. Pair-wise comparison showed that presence of CAC was associated with mild and moderate OSA but not with severe OSA. Mean CAC scores were significantly higher in patients with moderate and severe OSA than in patients without OSA, suggesting that CAC score increases with OSA severity. Since some analyses included a small number of studies (<3 studies), further studies are needed to confirm the results.

**Sensitivity analysis**

Sensitivity analyses were performed for the primary and secondary outcomes using a leave-one-out approach. The direction and magnitude of the combined estimates for the presence of CAC (Figure 4) and CAC score in AHI <15 vs. AHI ≥15 events/h (Figure 5B) did not markedly differ with the removal of any one study, indicating that the meta-analysis had good reliability and that the data was not overly influenced by any given study. Pooled difference in means of CAC score in AHI ≥5 vs. AHI <5 events/h was still >0 despite that the difference in means of CAC score became borderline significant after the removal of Weinreich et al. [17], indicating no obvious influence on the pooled estimate (Figure 5A).
CAC, other cardiovascular risk factors such as age, gender, BMI, diabetes, and hypertension were not considered in the meta-analysis. With regard to age, Arik et al. reported that age and AHI were independent predictors of CAC in patients with OSA [16]. The optimal cut-off values to predict CAC were age > 45 years and AHI > 16 events/h with a sensitivity of 88.9% and 77.8% and a specificity of 54.3% and 56.5%, respectively, and the combination of AHI > 16 and age > 45 had increased specificity (70.6%) and unchanged sensitivity (87%) for predicting subclinical atherosclerosis [16]. Patient age in most of the studies included in the meta-analysis was greater than 45 years, except in Arik et al. [16] Kepez et al. [20] and Sorajja et al. [18], which may have been reflected in the wide error bar of calculated OR in the analysis of CAC presence in Arik et al. (Figure 2(B)). With regard to sex, Medeiros et al. demonstrated that there was an independent association with moderate to severe OSA (AHI ≥ 15 events/h) and the presence of CAC in middle-aged women [32]. Similarly, Weinreich et al. showed that the severity of OSA was independently associated CAC score in women of any age, whereas the association was only observed in men aged ≥ 65 years [17]. In contrast, Seo et al. recruited predominantly male (92.8%) subjects who were aged < 65 years, and the results showed that AHI and moderate to severe OSA were not associated with the presence of CAC after adjustment for BMI [19]. A similar study conducted by Kim et al. recruited middle aged-men (40–49 years old) who were classified into AHI severity quartiles [21]. The results also showed that the association between AHI in the fourth quartile and CAC was no longer significant after further adjustment for BMI. The inconsistency of results from the Seo et al. [19] and Kim et al. [21] studies may be the result of enrolment

**Figure 3.** Forest plot comparing CAC scores between (A) AHI ≥ 5 vs. < 5 events/h and (B) AHI ≥ 15 vs. < 15 events/h. Abbreviations: 95% CI, 95% confidence interval of difference in means (lower limit and upper limit).
of only Asian patients [36,37] and the lower prevalence of hypertension in these studies [38]. Moreover, with regard to BMI, it was reported that there was an independent association between BMI ≥ 23.0 kg/m² and CAC regardless of OSA severity [21]. Similar results were also found among middle-aged men and women in a study published by Luyster et al., which showed that among subjects with BMI ≥ 30 kg/m², OSA severity was not associated with the presence of CAC [34]. In addition, Matthews et al. reported that such association became nonsignificant after adjusting for BMI in middle-aged men and women [35]. These findings suggest that obesity is a confounder of the association between OSA and subclinical CAD. Further research is warranted to confirm this finding and to identify other possible confounders.

Although the current study showed that patients with OSA had higher mean CAC score than those without OSA, CAC scores were presented differently among studies, including as mean ± SD, mean (IQR), median (IQR), or median (range), and the reported SD, IQR, or range were extremely large (Table 2). This indicates that the distribution of CAC score within each OSA severity group was heterogeneous. Moreover, calculation of mean and SD from mean and IQR, median and IQR, or median and range may result in deviation from the variance of the data, which could introduce bias in the pooling. In addition, the correlation of AHI and CAC score was uncertain. A weak (r = 0.342, p = .003) or even non-linear (r = 0.02, p = .90) correlation was found between AHI values and CAC score [16,31]. These results suggest that CAC may be more

Figure 4. Sensitivity analyses of presence of CAC between (A) AHI ≥ 5 vs. < 5 events/h and (B) AHI ≥ 15 vs. < 15 events/h. Abbreviations: 95% CI, 95% confidence interval of odds ratio (lower limit and upper limit).
influenced by the duration of morbidity attributable to sleep apnoea rather than exhibiting a temporal increase in disease severity [31]. On the other hand, log-transformed AHI was independently associated with log-transformed CAC score. There was an association between doubling of AHI with an increase of CAC score in men aged 65 years (19%, 95% CI = 0.000–42%) and in women of any age (17%, 95% CI = 3–33%) [17]. Although the pair-wise comparison in the current study partially showed that CAC score may increase with increased severity of OSA, significant association between CAC presence and severe OSA was not observed. A cluster analysis reporting on a very severe OSA phenotype based on AHI found that AHI had no direct link to cardiovascular diseases, and that for moderate-to-severe OSA phenotype, OSA severity was not associated with any comorbidities. The author speculated that the entity of nocturnal desaturation might have a stronger effect on the development of comorbidities than simply the frequency of apneas and hypopneas [39]. Further studies are warranted to examine the correlation between AHI and CAC score and the impact of additional variables on CAC.

In some of the included studies, HSAT instead of the gold standard PSG was used for diagnosis of OSA. Although HSAT has been validated with acceptable performance in identifying OSA, it may misestimate AHI [40,41,42]. A previous study reported that for PSG, an AHI cut-off of ≥5 events/h obtained the best receiver operating characteristic curve. For home respiratory polygraphy, an AHI cut-off of ≥10 events/h successfully confirmed the diagnosis [40]. The present study echoed the previous study showing that the presence of CAC was increased by a factor of 3.54 in in-hospital/laboratory PSG relative to a factor of 1.59

Figure 5. Sensitivity analysis of CAC score between (A) AHI ≥5 vs.<5 events/h and (B) AHI ≥15 vs.<15 events/h. Abbreviations: 95% CI, 95% confidence interval of difference in means (lower limit and upper limit).
in HSAT for an AHI cut-off of ≥5 events/h. Moreover, mean CAC score was not significantly different in the comparison of AHI of ≥5 vs. <5 events/h for HSAT. In addition, it was reported that AHI value for diagnosis of OSA using portable monitors ranged between 5 and 20 in different studies [43].

A previous systematic review evaluated the relationship between OSA and subclinical cardiovascular disease assessed by CAC, carotid intima-media thickness, flow-mediated dilation, and pulse wave velocity. In general, most of studies showed a correlation between markers of subclinical atherosclerosis and OSA severity. Of the six reviewed studies that used CAC to assess for subclinical atherosclerosis, four studies showed an independent correlation between AHI and CAC score, and two studies showed that the correlation became nonsignificant after adjusting for BMI or age [44]. Therefore, the findings of the previous review were consistent with those of the current study showing the positive association between the presence of OSA and subclinical CAD. Moreover, several previous meta-analyses have shown the association between OSA and subclinical CAD, as assessed by carotid intima-media thickness, flow-mediated dilation, and pulse wave velocity [45–47]. The present meta-analysis further confirmed the correlation through the assessment of CAC.

The present study has some limitations that should be considered. First, most of included studies were cross-sectional in design in which temporal or causal relationships between sleep apnoea and CAC presence cannot be determined and selection bias may occur. Second, patients with CAC scores of >100 were reported to have the greatest risk of coronary events [13]. The cut-off value for CAC presence was >0 in most of the eligible studies, and the association of low CAC scores and the risk of CAD may be questionable. Two eligible studies reported the outcomes of patients with a CAC score >100 [32,35] and one study reported the outcomes of patients with a CAC score >400 [33]. Although the study number was small, the pooled results show a glimpse that the OSA group had a higher rate of CAC presence for comparison of AHI ≥5 vs. <5 events/h for both CAC scores >100 and >400 (Table S1). Third, as mentioned above, CAC scores reported by the included studies were in different forms and their distribution indicated high heterogeneity. Therefore, the data may have been over-analyzed for pooling, which could result in bias. Fourth, the comparison groups in the current analysis were derived from combined data of different OSA severity groups, which could also result in data over-analysis.
Further analysis such as meta-regression of the potential confounding factors was not conducted. Moreover, adjusted data reported in the included studies were not adjusted for identical confounding factors, making pooling impossible. Indeed, the best approach would be to conduct analyses using individual patient data. Lastly, the current study only considered AHI to quantify OSA severity. Several studies have reported that AHI failed to characterise the degree and duration of oxygen desaturation and cannot fully predict the symptoms and prognosis of sleep apnoea [39, 48, 49]. Therefore, other factors such as hypoxic burden can be introduced to better measure the severity of OSA.

In conclusion, this systematic review and meta-analysis found that the presence of CAC and CAC score may be associated with the presence of OSA. However, potential confounders such as age, gender, and BMI and the diversity of CAC scores may affect this association. Moreover, due to the limitations of the analysis of CAC score and OSA, it is recommended that other markers of subclinical CAD in addition to CAC score be considered in clinical practice when managing patients with OSA. It may be helpful for further research to explore these issues with individual patient-level meta-analysis.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

National Natural Science Foundation of China [81870322, 81670222], Beijing Municipal Science and Technology Commission [Z181100001718060], the Natural Science Foundation of Beijing, China [7191002], Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX201710], Beijing Municipal Administration of Hospitals’ Ascent Plan [DFL20180601], Beijing Lab for Cardiovascular Precision Medicine, Beijing, China [PXM2018_014226_000013], and the Capital Health Research and Development of Special Fund [2018-1-2061].

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

References

[1] Tuleta I, Pabst S, Juergens UR, et al. Obstructive sleep apnoea as a risk factor for atherosclerosis - implication for preventive and personalised treatment. Epma J. 2011;2(1):39–47.
[2] American Academy of Sleep Medicine, European Respiratory Society, Australasian Sleep Association, American Thoracic Society. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999;22(5):667–689.
[3] Benjafeli AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687–698.
[4] Floras JS. Sleep apnea and cardiovascular disease: an enigmatic risk factor. Circ Res. 2018;122(12):1741–1764.
[5] Pizarro C, Schaefer K, Kimeu I, et al. Underdiagnosis of obstructive sleep apnoea in peripheral arterial disease. Respiration. 2015;89(3):214–220.
[6] Schahab N, Sudan S, Schaefer C, et al. Sleep apnoea is common in severe peripheral arterial disease. PLOS One. 2017;12(7):e0181733.
[7] Utriainen KT, Airaksinen JK, Polo O, et al. Unrecognised obstructive sleep apnoea is common in severe peripheral arterial disease. Eur Respir J. 2013;41(3):616–620.
[8] Knauert M, Naik S, Gillespie MB, et al. Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. World J Otorhinolaryngol Head Neck Surg. 2015;1(1):17–27.
[9] Fan J, Wang X, Ma X, et al. Association of obstructive sleep apnea with cardiovascular outcomes in patients with acute coronary syndrome. J Am Heart Assoc. 2019;8(2):e010826.
[10] Wang X, Fan JY, Zhang Y, et al. Association of obstructive sleep apnea with cardiovascular outcomes after percutaneous coronary intervention: a systematic review and meta-analysis. Medicine. 2018;97(17):e0621.
[11] Wang X, Zhang Y, Dong Z, et al. Effect of continuous positive airway pressure on long-term cardiovascular outcomes in patients with coronary artery disease and obstructive sleep apnea: a systematic review and meta-analysis. Respir Res. 2018;19(1):61.
[12] Burge MR, Eaton RP, Comerci G, et al. Management of asymptomatic patients with positive coronary artery calcium scans. J Endocr Soc. 2017;1(6):588–599.
[13] Dettmann R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–1345.
[14] Cowlwright M, Rice K, Budoff MJ, et al. Differentiation of severe coronary artery calcification in the multi-ethnic study of atherosclerosis. Atherosclerosis. 2011;219(2):616–622.
[15] Neves PO, Andrade J, Moncao H. Coronary artery calcium score: current status. Radiol Bras. 2017;50(3):182–189.
[16] Arik B, Inci MF, Gumus C, et al. Advanced age and apnea-hypopnea index predict subclinical atherosclerosis in patients with obstructive sleep apnea syndrome. Multidiscip Respir Med. 2013;8(1):9.
Weinreich G, Wessendorf TE, Erdmann T, et al. Association of obstructive sleep apnoea with subclinical coronary atherosclerosis. Atherosclerosis. 2013;231(2):191–197.

Soraja D, Gami AS, Somers VK, et al. Independent association between obstructive sleep apnea and subclinical coronary artery disease. Chest. 2008;133(4):927–933.

Seo MY, Lee JY, Hahn JY, et al. Association of obstructive sleep apnea with subclinical cardiovascular disease predicted by coronary artery calcium score in asymptomatic subjects. Am J Cardiol. 2017;120(4):577–581.

Kepez A, Niksarlıoğlu EYÖ, Hazırolan T, et al. Evaluation of association between obstructive sleep apnea and coronary risk scores predicted by tomographic coronary calcium scoring in asymptomatic patients. Anadolu Kardiyol Derg. 2011;11(5):428–435.

Kim SH, Cho GY, Baik I, et al. Association of coronary artery calcification with obstructive sleep apnea and obesity in middle-aged men. Nutr Metab Cardiovasc Dis. 2010;20(8):575–582.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.

Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2–10.

Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Statist Med. 1998;17(8):841–856.

Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol. 1999;150(2):206–215.

Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.

Kim S, Lee KY, Lim NH, et al. Relationship of obstructive sleep apnoea severity and subclinical systemic atherosclerosis. Eur Respir J. 2020;55(2):1900959.

Bikov A, Kolossvary M, Jermendy AL, et al. Comprehensive coronary plaque assessment in patients with obstructive sleep apnea. J Sleep Res. 2019;28(5):e12828.

Shpilsky D, Ergou S, Patel SR, et al. Association of obstructive sleep apnea with microvascular endothelial dysfunction and subclinical coronary artery disease in a community-based population. Vasc Med. 2018;23(4):331–339.

Hamaoka T, Murai H, Kaneko S, et al. Significant association between coronary artery low-attenuation plaque volume and apnea-hypopnea index, but not muscle sympathetic nerve activity, in patients with obstructive sleep apnea syndrome. Circ J. 2018;82(11):2852–2860.

Medeiros AK, Coutinho RQ, Barros IM, et al. Obstructive sleep apnea is independently associated with subclinical coronary atherosclerosis among middle-aged women. Sleep Breath. 2017;21(1):77–83.

Lutsey PL, McClelland RL, Durez D, et al. Objectively measured sleep characteristics and prevalence of coronary artery calcification: the multi-ethnic study of atherosclerosis sleep study. Thorax. 2015;70(9):880–887.

Luyster FS, Kip KE, Aiyer AN, et al. Relation of obstructive sleep apnea to coronary artery calcium in non-obese versus obese men and women aged 45–75 years. Am J Cardiol. 2014;114(11):1690–1694.

Matthews KA, Strollo PJ Jr., Hall M, et al. Associations of Framingham risk score profile and coronary artery calcification with sleep characteristics in middle-aged men and women: Pittsburgh Sleep SCORE study. Sleep. 2011;34(6):711–716.

Orakzai SH, Orakzai RH, Nasir K, et al. Subclinical coronary atherosclerosis: racial profiling is necessary! Am Heart J. 2006;152(5):819–827.

Fair JM, Kiazand A, Varady A, et al. Ethnic differences in coronary artery calcium in a healthy cohort aged 60 to 69 years. Am J Cardiol. 2007;100(6):981–985.

Erbel R, Lehmann N, Mohlenkamp S, et al. Subclinical coronary atherosclerosis predicts cardiovascular risk in different stages of hypertension: result of the Heinz Nixdorf Recall Study. Hypertension. 2012;59(1):44–53.

Lacedonia D, Carpagnano GE, Sabato R, et al. Characterization of obstructive sleep apnea-hypopnea syndrome (OSA) population by means of cluster analysis. J Sleep Res. 2016;25(6):724–730.

Masa JF, Corral J, Pereira R, et al. Effectiveness of home respiratory polygraphy for the diagnosis of sleep apnoea and hypopnoea syndrome. Thorax. 2011;66(7):567–573.

Rosen CL, Auckley D, Benca R, et al. A multisite randomized trial of portable sleep studies and positive airway pressure autotitration versus laboratory-based polysomnography for the diagnosis and treatment of obstructive sleep apnea: the HomePAP study. Sleep. 2012;35(6):757–767.

Ragette R, Wang Y, Weinreich G, et al. Diagnostic performance of single airflow channel recording (ApneaLink) in home diagnosis of sleep apnea. Sleep Breath. 2010;14(2):109–114.

Walia R, Achilefu A, Crawford S, et al. Are at-home sleep studies performed using portable monitors (PMs) as effective at diagnosing obstructive sleep apnea (OSA) in adults as sleep laboratory-based polysomnography (PSG)? J Okla State Med Assoc. 2014;107(12):642–644.

Ali SS, Oni ET, Warraich HJ, et al. Systematic review on noninvasive assessment of subclinical cardiovascular disease in obstructive sleep apnea: new kid on the block!. Sleep Med Rev. 2014;18(5):379–391.

Zhou M, Guo B, Wang Y, et al. The association between obstructive sleep apnea and carotid intima-
media thickness: a systematic review and meta-analysis. Angiology. 2017;68(7):575–583.

[46] Wang Y, Xu H, Qian Y, et al. Patients with obstructive sleep apnea display decreased flow-mediated dilatation: evidence from a meta-analysis. Med Sci Monit. 2017;23:1069–1082.

[47] Wang J, Yu W, Gao M, et al. Impact of obstructive sleep apnea syndrome on endothelial function, arterial stiffening, and serum inflammatory markers: an updated meta-analysis and metaregression of 18 studies. J Am Heart Assoc. 2015;4(11):e002454.

[48] Punjabi NM. COUNTERPOINT: is the apnea-hypopnea index the best way to quantify the severity of sleep-disordered breathing? No. Chest. 2016;149(1):16–19.

[49] Chen F, Chen K, Zhang C, et al. Evaluating the clinical value of the hypoxia burden index in patients with obstructive sleep apnea. Postgrad Med. 2018;130(4):436–441.